Your browser doesn't support javascript.
loading
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically.
Wang, Xin-Shuai; Ding, Xue-Zhen; Li, Xiao-Cen; He, Yixuan; Kong, De-Jiu; Zhang, Li; Hu, Xiao-Chen; Yang, Jun-Qiang; Zhao, Meng-Qi; Gao, She-Gan; Lin, Tzu-Yin; Li, Yuanpei.
Affiliation
  • Wang XS; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Ding XZ; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Li XC; Department of Biochemistry & Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
  • He Y; Department of Biochemistry & Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
  • Kong DJ; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Zhang L; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Hu XC; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Yang JQ; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Zhao MQ; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
  • Gao SG; Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China. Electronic address: sggao2016@163.com.
  • Lin TY; Department of Internal Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA. Electronic address: tylin@ucdavis.edu.
  • Li Y; Department of Biochemistry & Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA. Electronic address: lypli@ucdavis.edu.
Nanomedicine ; 14(7): 2103-2114, 2018 10.
Article in En | MEDLINE | ID: mdl-30047470
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma, Squamous Cell / Chromones / Drug Delivery Systems / Nanomedicine / Class I Phosphatidylinositol 3-Kinases / Docetaxel / Aniline Compounds Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male / Middle aged Language: En Journal: Nanomedicine Journal subject: BIOTECNOLOGIA Year: 2018 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma, Squamous Cell / Chromones / Drug Delivery Systems / Nanomedicine / Class I Phosphatidylinositol 3-Kinases / Docetaxel / Aniline Compounds Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male / Middle aged Language: En Journal: Nanomedicine Journal subject: BIOTECNOLOGIA Year: 2018 Type: Article Affiliation country: China